PHS
NTLA icon

PFM Health Sciences’s Intellia Therapeutics NTLA Stock Holding History

PFM Health Sciences’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-85,000
Closed -$13.8M – 97
2021
Q2 		$13.8M Buy
+85,000
New +$6.62M 0.43% 58

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

PFM Health Sciences's NTLA Position: Q4 2022 in Review

PFM Health Sciences sold out of Intellia Therapeutics (NTLA) in Q4 2022, closing a stake of 344,868 shares — an estimated $19.3M sold.

PFM Health Sciences first reported a position in NTLA in Q1 2021 and held it in 7 quarters. The position peaked at $28.9M in Q2 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q4 2022.

  • PFM Health Sciences reported no remaining Intellia Therapeutics position as of Q4 2022 after selling out during the quarter.
  • PFM Health Sciences sold 344,868 Intellia Therapeutics shares in Q4 2022, an estimated $19.3M.
  • PFM Health Sciences first reported a position in Intellia Therapeutics in Q1 2021 and held it in 7 quarters.
  • PFM Health Sciences's Intellia Therapeutics position peaked at $28.9M in Q2 2021.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2022.

Based on PFM Health Sciences's 13F filing for Q4 2022, filed 14 Feb 2023.